OBJECTIVE: Growth hormone (GH)/insulin-like growth factor (IGF) axis and insulin are key determinants of bone remodelling. Homozygous mutations in the GH-releasing hormone receptor (GHRHR) gene (GHRHR) are a frequent cause of genetic isolated GH deficiency (IGHD). Heterozygosity for GHRHR mutation causes changes in body composition and possibly an increase in insulin sensitivity, but its effects on bone quality are still unknown. The objective of this study was to assess the bone quality and metabolism and its correlation with insulin sensitivity in subjects heterozygous for a null mutation in the GHRHR. PATIENTS AND METHODS: A cross-sectional study was performed on 76 normal subjects (68·4% females) (N/N) and 64 individuals (64·1% females) heterozygous for a mutation in the GHRHR (MUT/N). Anthropometric features, quantitative ultrasound (QUS) of the heel, bone markers [osteocalcin (OC) and CrossLaps], IGF-I, glucose and insulin were measured, and homeostasis model assessment of insulin resistance (HOMA(IR) ) was calculated. RESULTS: There were no differences in age or height between the two groups, but weight (P = 0·007) and BMI (P = 0·001) were lower in MUT/N. There were no differences in serum levels of IGF-I, glucose, T-score or absolute values of stiffness and OC, but insulin (P = 0·01), HOMA(IR) (P = 0·01) and CrossLaps (P = 0·01) were lower in MUT/N. There was no correlation between OC and glucose, OC and HOMA(IR) in the 140 individuals as a whole or in the separate MUT/N or N/N groups. CONCLUSIONS: This study suggests that one allele mutation in the GHRHR gene has a greater impact on energy metabolism than on bone quality.
OBJECTIVE:Growth hormone (GH)/insulin-like growth factor (IGF) axis and insulin are key determinants of bone remodelling. Homozygous mutations in the GH-releasing hormone receptor (GHRHR) gene (GHRHR) are a frequent cause of genetic isolated GH deficiency (IGHD). Heterozygosity for GHRHR mutation causes changes in body composition and possibly an increase in insulin sensitivity, but its effects on bone quality are still unknown. The objective of this study was to assess the bone quality and metabolism and its correlation with insulin sensitivity in subjects heterozygous for a null mutation in the GHRHR. PATIENTS AND METHODS: A cross-sectional study was performed on 76 normal subjects (68·4% females) (N/N) and 64 individuals (64·1% females) heterozygous for a mutation in the GHRHR (MUT/N). Anthropometric features, quantitative ultrasound (QUS) of the heel, bone markers [osteocalcin (OC) and CrossLaps], IGF-I, glucose and insulin were measured, and homeostasis model assessment of insulin resistance (HOMA(IR) ) was calculated. RESULTS: There were no differences in age or height between the two groups, but weight (P = 0·007) and BMI (P = 0·001) were lower in MUT/N. There were no differences in serum levels of IGF-I, glucose, T-score or absolute values of stiffness and OC, but insulin (P = 0·01), HOMA(IR) (P = 0·01) and CrossLaps (P = 0·01) were lower in MUT/N. There was no correlation between OC and glucose, OC and HOMA(IR) in the 140 individuals as a whole or in the separate MUT/N or N/N groups. CONCLUSIONS: This study suggests that one allele mutation in the GHRHR gene has a greater impact on energy metabolism than on bone quality.
Authors: Francisco J A de Paula; Ingrid Dick-de-Paula; Sheila Bornstein; Bahman Rostama; Phuong Le; Sutada Lotinun; Roland Baron; Clifford J Rosen Journal: Calcif Tissue Int Date: 2011-06-03 Impact factor: 4.333
Authors: Bu B Yeap; S A Paul Chubb; Leon Flicker; Kieran A McCaul; Peter R Ebeling; John P Beilby; Paul E Norman Journal: Eur J Endocrinol Date: 2010-05-25 Impact factor: 6.664
Authors: Carla R P Oliveira; Roberto Salvatori; Rafael A Meneguz-Moreno; Manuel H Aguiar-Oliveira; Rossana M C Pereira; Eugênia H A Valença; Vanessa P Araujo; Natália T Farias; Débora C R Silveira; Jose G H Vieira; Jose A S Barreto-Filho Journal: J Clin Endocrinol Metab Date: 2009-12-16 Impact factor: 5.958
Authors: Jose Manuel Fernández-Real; Mikel Izquierdo; Francisco Ortega; Esteban Gorostiaga; Javier Gómez-Ambrosi; Jose Maria Moreno-Navarrete; Gema Frühbeck; Cristina Martínez; Fernando Idoate; Javier Salvador; Lluis Forga; Wifredo Ricart; Javier Ibañez Journal: J Clin Endocrinol Metab Date: 2008-10-14 Impact factor: 5.958
Authors: Francisco J A de Paula; Miburge B Góis-Júnior; Manuel H Aguiar-Oliveira; Francisco de A Pereira; Carla R P Oliveira; Rossana M C Pereira; Catarine T Farias; Tábita A R Vicente; Roberto Salvatori Journal: Clin Endocrinol (Oxf) Date: 2008-05-20 Impact factor: 3.478
Authors: Alana L Andrade-Guimarães; Manuel H Aguiar-Oliveira; Roberto Salvatori; Vitor O Carvalho; Fabiano Alvim-Pereira; Carlos R Araújo Daniel; Giulliani A Moreira Brasileiro; Ananda A Santana-Ribeiro; Hugo A Santos-Carvalho; Carla R P Oliveira; Edgar R Vieira; Miburge B Gois-Junior Journal: Endocrine Date: 2018-09-24 Impact factor: 3.633